Literature DB >> 29756399

Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.

Guangwei Du1, Mechelle M Lewis1,2, Christopher Sica3, Lu He4, James R Connor5, Lan Kong6, Richard B Mailman1,2, Xuemei Huang1,2,3,5,7.   

Abstract

BACKGROUND: Susceptibility MRI may capture Parkinson's disease-related pathology. This study delineated longitudinal changes in different substantia nigra regions.
METHODS: Seventy-two PD patients and 62 controls were studied at both baseline and after 18 months with MRI. R2* and quantitative susceptibility mapping values from the substantia nigra pars compacta and substantia nigra pars reticulata were calculated. Mixed-effects models compared controls with PD or PD subgroups having different disease durations: early (<1 year), middle (<5 years, middle-stage PD), and late (>5 years, late-stage PD). Pearson's correlation assessed associations between imaging and clinical measures.
RESULTS: At baseline, R2* and quantitative susceptibility mapping were higher in both the substantia nigra pars compacta and substantia nigra pars reticulata in all PD patients (group effect, P ≤ 0.003). Longitudinally, the substantia nigra pars compacta R2* showed a faster increase in PD compared with controls (time × group, P = 0.002), whereas quantitative susceptibility mapping did not (P = 0.668). The substantia nigra pars reticulata R2* and quantitative susceptibility mapping did not differ between PD and controls (time × group, P ≥ 0.084), although both decreased longitudinally (time effect, P ≤ 0.004). Baseline substantia nigra pars compacta R2* was higher in all PD subgroups (group, P ≤ 0.006), but showed a significantly faster increase only in later-stage PD (time × group, P < 0.0001) that correlated with changes in nonmotor symptoms (r = 0.746, P = 0.002). Baseline substantia nigra pars reticulata quantitative susceptibility mapping was higher in middle-stage PD and later-stage PD (group, P ≤ 0.002), but showed a longitudinal decrease (time × group, P = 0.004) only in later-stage PD that correlated with changes in motor signs (r = 0.837, P < 0.001).
CONCLUSION: Susceptibility MRI revealed distinct patterns of PD progression in the substantia nigra pars compacta and substantia nigra pars reticulata. The different patterns are particularly clear in later-stage patients. These findings may resolve past controversies and have implications in the pathophysiological processes during PD progression.
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; magnetic resonance imaging; quantitative susceptibility mapping; substantia nigra pars compacta (SNc); substantia nigra pars reticulata (SNr)

Mesh:

Year:  2018        PMID: 29756399      PMCID: PMC6185755          DOI: 10.1002/mds.27318

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  43 in total

1.  Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.

Authors:  Patrice Péran; Andrea Cherubini; Francesca Assogna; Fabrizio Piras; Carlo Quattrocchi; Antonella Peppe; Pierre Celsis; Olivier Rascol; Jean-François Démonet; Alessandro Stefani; Mariangela Pierantozzi; Francesco Ernesto Pontieri; Carlo Caltagirone; Gianfranco Spalletta; Umberto Sabatini
Journal:  Brain       Date:  2010-08-23       Impact factor: 13.501

Review 2.  Imaging iron stores in the brain using magnetic resonance imaging.

Authors:  E Mark Haacke; Norman Y C Cheng; Michael J House; Qiang Liu; Jaladhar Neelavalli; Robert J Ogg; Asadullah Khan; Muhammad Ayaz; Wolff Kirsch; Andre Obenaus
Journal:  Magn Reson Imaging       Date:  2005-01       Impact factor: 2.546

3.  Susceptibility phase imaging with comparison to R2 mapping of iron-rich deep grey matter.

Authors:  Andrew J Walsh; Alan H Wilman
Journal:  Neuroimage       Date:  2011-04-13       Impact factor: 6.556

4.  Caffeine intake, smoking, and risk of Parkinson disease in men and women.

Authors:  Rui Liu; Xuguang Guo; Yikyung Park; Xuemei Huang; Rashmi Sinha; Neal D Freedman; Albert R Hollenbeck; Aaron Blair; Honglei Chen
Journal:  Am J Epidemiol       Date:  2012-04-13       Impact factor: 4.897

5.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

Authors:  David Devos; Caroline Moreau; Jean Christophe Devedjian; Jérome Kluza; Maud Petrault; Charlotte Laloux; Aurélie Jonneaux; Gilles Ryckewaert; Guillaume Garçon; Nathalie Rouaix; Alain Duhamel; Patrice Jissendi; Kathy Dujardin; Florent Auger; Laura Ravasi; Lucie Hopes; Guillaume Grolez; Wance Firdaus; Bernard Sablonnière; Isabelle Strubi-Vuillaume; Noel Zahr; Alain Destée; Jean-Christophe Corvol; Dominik Pöltl; Marcel Leist; Christian Rose; Luc Defebvre; Philippe Marchetti; Z Ioav Cabantchik; Régis Bordet
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

7.  Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.

Authors:  E C Hirsch; J P Brandel; P Galle; F Javoy-Agid; Y Agid
Journal:  J Neurochem       Date:  1991-02       Impact factor: 5.372

8.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain.

Authors:  E Sofic; P Riederer; H Heinsen; H Beckmann; G P Reynolds; G Hebenstreit; M B Youdim
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

9.  Stability of R2* and quantitative susceptibility mapping of the brain tissue in a large scale multi-center study.

Authors:  Rongpin Wang; Guangyou Xie; Maoxiong Zhai; Zhongping Zhang; Bing Wu; Dandan Zheng; Nan Hong; Tao Jiang; Baohong Wen; Jingliang Cheng
Journal:  Sci Rep       Date:  2017-03-28       Impact factor: 4.379

10.  Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?

Authors:  Lucie Hopes; Guillaume Grolez; Caroline Moreau; Renaud Lopes; Gilles Ryckewaert; Nicolas Carrière; Florent Auger; Charlotte Laloux; Maud Petrault; Jean-Christophe Devedjian; Regis Bordet; Luc Defebvre; Patrice Jissendi; Christine Delmaire; David Devos
Journal:  PLoS One       Date:  2016-04-01       Impact factor: 3.240

View more
  28 in total

1.  Magnetic resonance T1w/T2w ratio: A parsimonious marker for Parkinson disease.

Authors:  Guangwei Du; Mechelle M Lewis; Christopher Sica; Lan Kong; Xuemei Huang
Journal:  Ann Neurol       Date:  2018-12-19       Impact factor: 10.422

2.  Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Authors:  Niels Bergsland; Eleonora Tavazzi; Ferdinand Schweser; Dejan Jakimovski; Jesper Hagemeier; Michael G Dwyer; Robert Zivadinov
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

Review 3.  Nigrosome 1 imaging: technical considerations and clinical applications.

Authors:  Eung Yeop Kim; Young Hee Sung; Jongho Lee
Journal:  Br J Radiol       Date:  2019-06-05       Impact factor: 3.039

4.  Multimodal MRI evaluation of parkinsonian limbic pathologies.

Authors:  Ernest W Wang; Guangwei Du; Mechelle M Lewis; Eun-Young Lee; Sol De Jesus; Sangam Kanekar; Lan Kong; Xuemei Huang
Journal:  Neurobiol Aging       Date:  2019-01-16       Impact factor: 4.673

5.  Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.

Authors:  Niels Bergsland; Robert Zivadinov; Ferdinand Schweser; Jesper Hagemeier; David Lichter; Thomas Guttuso
Journal:  Mov Disord       Date:  2019-06-10       Impact factor: 10.338

6.  Characterization of age-related microstructural changes in locus coeruleus and substantia nigra pars compacta.

Authors:  Jason Langley; Sana Hussain; Justino J Flores; Ilana J Bennett; Xiaoping Hu
Journal:  Neurobiol Aging       Date:  2019-11-29       Impact factor: 4.673

Review 7.  Structural Imaging in Parkinson's Disease: New Developments.

Authors:  Stéphane Prange; Elise Metereau; Stéphane Thobois
Journal:  Curr Neurol Neurosci Rep       Date:  2019-06-18       Impact factor: 5.081

8.  Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes.

Authors:  Mechelle M Lewis; Guangwei Du; Jennifer Baccon; Amanda M Snyder; Ben Murie; Felicia Cooper; Christy Stetter; Lan Kong; Christopher Sica; Richard B Mailman; James R Connor; Xuemei Huang
Journal:  Mov Disord       Date:  2018-05-14       Impact factor: 10.338

Review 9.  Longitudinal Progression Markers of Parkinson's Disease: Current View on Structural Imaging.

Authors:  Jing Yang; Roxana G Burciu; David E Vaillancourt
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-02       Impact factor: 5.081

10.  Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts.

Authors:  Jason Langley; Naying He; Daniel E Huddleston; Shengdi Chen; Fuhua Yan; Bruce Crosson; Stewart Factor; Xiaoping Hu
Journal:  Mov Disord       Date:  2018-12-30       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.